- Home
- GNLX vs ENTX Comparison
GNLX vs ENTX Comparison
Compare GNLX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ENTX
- Stock Information
- Founded
- GNLX 2001
- ENTX 2010
- Country
- GNLX United States
- ENTX Israel
- Employees
- GNLX N/A
- ENTX N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- ENTX Health Care
- Exchange
- GNLX Nasdaq
- ENTX Nasdaq
- Market Cap
- GNLX 94.0M
- ENTX 104.0M
- IPO Year
- GNLX 2023
- ENTX 2018
- Fundamental
- Price
- GNLX $2.45
- ENTX $1.94
- Analyst Decision
- GNLX Strong Buy
- ENTX Strong Buy
- Analyst Count
- GNLX 4
- ENTX 1
- Target Price
- GNLX $17.75
- ENTX $10.00
- AVG Volume (30 Days)
- GNLX 159.0K
- ENTX 35.9K
- Earning Date
- GNLX 05-06-2025
- ENTX 05-09-2025
- Dividend Yield
- GNLX N/A
- ENTX N/A
- EPS Growth
- GNLX N/A
- ENTX N/A
- EPS
- GNLX N/A
- ENTX N/A
- Revenue
- GNLX N/A
- ENTX $223,000.00
- Revenue This Year
- GNLX N/A
- ENTX N/A
- Revenue Next Year
- GNLX N/A
- ENTX N/A
- P/E Ratio
- GNLX N/A
- ENTX N/A
- Revenue Growth
- GNLX N/A
- ENTX N/A
- 52 Week Low
- GNLX $1.60
- ENTX $1.41
- 52 Week High
- GNLX $5.89
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- GNLX 44.96
- ENTX 47.15
- Support Level
- GNLX $2.42
- ENTX $1.69
- Resistance Level
- GNLX $2.78
- ENTX $2.08
- Average True Range (ATR)
- GNLX 0.21
- ENTX 0.13
- MACD
- GNLX 0.00
- ENTX -0.02
- Stochastic Oscillator
- GNLX 28.30
- ENTX 58.14
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.